Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MRT5407 in Adults
NCT05553301Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2022
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of MRT5407 in influenza, sponsored by Sanofi. Started Oct 2022; status: completed.
02
Drugs
MRT5407
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05553301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553301.